EICHORCondition: Myelodysplastic Syndromes · Sponsor: Taiho Oncology, Inc.
Multicenter, open-label study of various ASTX727 LD doses and schedules to assess safety, pharmacodynamics, pharmacokinetics, and hematologic response in subjects with International Prognostic Scoring System (IPSS) risk category of low-risk or Intermediate-1 MDS. This study will be conducted in two phases. In phase 1 subjects will be randomized into 3 cohorts in a 28-day cycles. Phase 2, 80 new subjects will be randomized in a 1:1 ratio into 2 doses/schedules.
This description comes directly from the study's public registry record.
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
| The University of Alabama at Birmingham | Birmingham, Alabama, United States | — |
| University of Colorado, Anschutz Cancer Pavilion | Aurora, Colorado, United States | — |
| Yale Cancer Center | New Haven, Connecticut, United States | — |
| Mayo Clinic Florida | Jacksonville, Florida, United States | — |
| BRCR Medical Center Inc. | Plantation, Florida, United States | — |
| Moffitt Cancer Center Site#507 | Tampa, Florida, United States | — |
| The University of Chicago | Chicago, Illinois, United States | — |
| Indiana University Health Hospital - Simon Cancer Center | Indianapolis, Indiana, United States | — |
| University of Kansas Clinical Research Center | Westwood, Kansas, United States | — |
| The Center for Cancer and Blood Disorders (RCCA MD LLC - Maryland Division) | Bethesda, Maryland, United States | — |
| Mayo Clinic | Rochester, Minnesota, United States | — |
| University of Nebraska Medical Center | Omaha, Nebraska, United States | — |
+ 17 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03502668